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The Rocky Road from Cancer Stem Cell 
Discovery to Diagnostic Applicability 




Since the discovery of the discretely isolatable highly tumorigenic tumor population with 
self renewal and differentiation properties (i.e. cancer stem cells, CSCs), it has been 
theorized that their quantification in tumor tissues would have significant prognostic value. 
Based on their increased tumorigenicity and stem cell like qualities, it is postulated that 
patients with elevated levels of CSCs would more likely suffer from an aggressive form of 
disease that is comparatively resistant to currently employed therapeutics. The results of the 
studies evaluating the prognostic value of CSC markers have been mixed, and cancer and 
marker dependant. Herein we review the currently known CSC markers for the more 
common cancers and their respective prognostic potential. In conclusion we will discuss 
what this data potentially reveals about the role of CSCs in tumor progression. 
2. Leukemia 
2.a Identified leukemia stem cell markers 
Acute myeloid leukemia (AML) is the result of malignant transformation of hematopoietic 
progenitor cells. These altered cells proliferate and lead to the accumulation of AML blasts. 
Only a minority population of all AML cells are capable of proliferating in vitro and in vivo. 
This suggests that AML cells are potentially organized in a hierarchy, with only the most 
primitive of these cells capable of maintaining the leukemic clone. This hypothesis was the 
basis for identifying the AML initiating cell and the CSC theory that arose from the 
subsequent studies. As such, CSCs were first identified in AML in 1990’s by John Dick’s 
group in Toronto, Canada (Bonnet and Dick, 1997; Lapidot et al., 1994). AML cells that were 
CD34+CD38- possessed stem cell like characteristics and de novo leukemia repopulating 
properties in immunocompromised mice (Bonnet and Dick, 1997). While leukemia initiating 
cells (LSCs) are in the range of 0.00002 to 0.02% of all unsorted mononuclear blood cells, 
LSCs were in the range of 0.02 to 2% in the CD34+CD38- sorted cells of tested patient 
samples (sorting resulting in approximate 100-1000 fold enrichment of the CSC population). 
In further similarity to normal stem cells, CD34+CD38- expression is also a unique identifier 
for hematopoietic stem cells (HSCs). Since then, other leukemic stem cell (LSC) markers 
have been identified. 
In 1997 and 1998, Blair et al. explored the use of other known HSC markers for the isolation 
of AML initiating cells and found that AML cells that are CD34+/HLA-DR-/CD71- and Thy1- 
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(CD90) had the CSC phenotype (Blair et al., 1997; Blair et al., 1998). Later that same group 
added lack of expression of c-kit (CD117) to the list of potential AML CSC markers, as AML 
cells from patients that were CD34+c-kit- were enriched for the CSC population (Blair and 
Sutherland, 2000). In 2000, Jordan et al., identified a cell surface molecule, interleukin-3 
receptor alpha chain (CD123) as being uniquely expressed on AML CSCs, but not HSCs 
(Jordan et al., 2000), allowing for a potential method of distinction between LSCs and HSCs.  
Other than the above described cell surface markers used for the isolation of CSCs, 
“functional markers” have been explored more recently. The functional marker strategy is 
based on stem cell characteristics, but does not rely on cell surface adhesion molecules for 
the viable isolation of a specific cell-subset. For example, Stemcell Technologies developed 
the aldefluor assay for the isolation of live hematopoietic stem cells based on increased 
expression of a cytoplasmic enzyme, aldehyde dehydrogenase (ALDH) isoform 1A1. 
ALDH1A1 is one of 19 ALDH isoforms expressed in humans, and it is a critical detoxifying 
enzyme responsible for oxidizing aldehydes to carboxylic acids (Marchitti et al., 2008). 
While, predominantly expressed in the epithelium of testis, brain, eye, liver, and kidney, 
ALDH1A1, is also found in high levels in hematopoietic and neural stem cells (Armstrong et 
al., 2004; Chute et al., 2006; Marchitti et al., 2008). ALDH1A1 is proposed to play a role in the 
differentiation of hematopoietic and neural stem cells via the oxidation of retinal to retinoic 
acid (Collins, 2008). Retinoic acid activates nuclear retinoic acid receptors (RARs) and RARs 
subsequently regulate the transcription of genes with RAREs (retinoic acid response 
elements). Furthermore, ALDH1A1 is known to metabolize and detoxify chemotherapeutics 
like cyclophosphamide (Magni et al., 1996), and is therefore thought to contribute to the 
innate chemotherapeutic resistance properties of hematopoietic stem cells. Using the 
aldefluor assay, Cheung et al., were the first to show that it was possible to isolate the LSCs 
based on the increased ALDH activity (Cheung et al., 2007). The researchers detected a 
population of ALDH+ AML cells in 14 of 43 patient samples. In the remaining 29 samples an 
ALDH+ population was rare or unidentifiable. The ALDH+ AML cells in most cases co-
expressed CD34+ (the previously identified marker) and engrafted significantly better than 
the ALDH- AML cells in immunocompromised mice. As discussed later, ALDH activity 
would become one of the few markers discovered that has applicability across a wide range 
of cancers. It can be said that ALDH activity is a universal CSC marker. 
2.b LSC markers as prognostic indicators 
Since the identification of a LSC population using cell surface markers it has been postulated 
that these markers could be used for diagnostic purposes, where patients with 
comparatively increased CSC numbers would theoretically suffer poorer outcomes. The 
results of the studies for leukemia are summarized in Table 1. Many of the cell surface 
markers had been evaluated separately for prognostic value prior to their discovery as 
potential CSC markers. For example as early as 1989, studies were being completed 
evaluating the prognostic value CD34 in AML (Borowitz et al., 1989; Campos et al., 1989). By 
2000, a study by Kanda et al., summarized the results from the then 22 completed 
independent studies on the prognostic relevance of CD34 for AML (Kanda et al., 2000). The 
authors’ review of the literature revealed a wide heterogeneity of results, with 12 studies 
concluding that increased CD34+ was associated with worse outcome, while the other 10 
studies failed to show the relevance of CD34 expression in predicting patient outcome 
(summarized in Table 1) (Kanda et al., 2000).  Kanda et al., concluded that given the wide 
variability of conclusions from the reports, CD34 expression could not be employed reliably 
as a prognostic marker (Kanda et al., 2000).  
www.intechopen.com
The Rocky Road from Cancer Stem Cell Discovery to Diagnostic Applicability   
 
337 
Similar disparity was seen for CD38 prognostic studies. For example, in 1993, Koehler et al. 
reported that CD38 expression failed to significantly correlate with the outcomes of 325 
patients of childhood acute lymphoblastic leukemia (ALL) (Koehler et al., 1993). In 2000, 
Keyhani et al. evaluated the levels of CD38 expression in the blasts of 304 AML and 138 ALL 
patients (Keyhani et al., 2000). Patients with the higher percentages of CD38+ cancer cells 
had the best outcomes, experiencing both longer times between remission and relapse and 
improved overall survival. Their results infer that patients with increased CD38- (LSC 
marker) cancer cells experienced the worse outcomes. However, lack of CD38 expression 
was only a significant independent risk factor for the AML patients, not ALL patients. In 
2003, Repp et al. assessed the prognostic value of a panel of 33 different CD molecules for 
AML (Repp et al., 2003). Among the panel, expression of CD38 and CD34 was quantified 
singly in 783 patient samples. As the CSC theory would predict, patients with increased 
CD34 expression or decreased CD38 expression had poorer overall outcomes. 
Other LSC markers have also been tested for their prognostic value individually. In a 1994 
immunophenotyping AML prognostic study (Bradstock et al., 1994), LSC proposed markers 
CD34, c-kit (CD117) and HLA-DR (Blair et al., 1998; Blair and Sutherland, 2000) were among 
the panel of CD antigens tested. CD34, c-kit and HLA-DR expression failed to correlate with 
patient outcome (Bradstock et al., 1994). A more recent study concluded that increased c-kit 
(CD117) expression correlated with worse outcomes for AML patients (Advani et al., 2008). 
This result was in direct disagreement with the CSC theory since it is the lack of c-kit 
expression in combination with CD34 expression that was used to identify LSCs (Blair and 
Sutherland, 2000). 
The above described studies suggest that the prognostic potential of LSC markers is not 
promising and clinically irrelevant. However, as discussed below, employed in combination, 
the prognostic potential of LSC markers becomes more apparent and the results therefore lend 
support to the CSC theory. In 2005, van Rhenen et al., quantified the frequency of CD34+CD38− 
cancer cells in 92 AML patients at time of diagnosis and reported worse outcomes for patients 
with increased CD34+CD38− cancer cells (van Rhenen A. et al., 2005). Patients with increased 
CD34+CD38− cancer cell frequency (>3.5%) relapsed on average 5.6 months post remission, 
while patients with lower CD34+CD38− cancer frequency relapsed on average 16 months post 
remission. The prognostic value of CD34+CD38− has also been observed in other leukemias. 
Recently, Ebinger et al. quantified the frequency of CD34+CD38− leukemia blasts in 42 
childhood ALL cases (Ebinger et al., 2010). The researchers found that increased CD34+CD38− 
cancer cells was associated with increased minimal residual disease and thus poorer prognosis 
for this leukemia sub-type as well. Although future studies will be required for confirmation, it 
appears that using the CSC markers in combination is more relevant as a prognostic tool than 
their application as singly applied markers. 
Finally, with the more recent discovery that ALDH activity can be used as marker to isolate 
LSC (Cheung et al., 2007), ALDH activity is also being tested for prognostic value. Cheung 
et al. reported that increased ALDH activity in AML patient samples correlated significantly 
with the cytogenetic changes previously associated with unfavourable prognosis (Cheung et 
al., 2007). In 2009, Ran et al. compared the outcomes of 40 AML patients with higher 
percentages of ALDH+ cancer cells (>0.36%) to 28 patients with lower frequencies of 
ALDH+ cells (<0.36%) (Ran et al., 2009). Increased frequency of ALDH+ cells correlated 
significantly with decreased survival probability. We await the results of future studies that 
will test the prognostic potential of ALDH activity combined with the LSC cell surface 
markers.  
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CD34+ 145 X   (Campos et al., 1989) 
CD34+ 75 X   (Borowitz et al., 1989) 
CD34+ 96 X   (Geller et al., 1990) 
CD34+ 27 X   (Guinot et al., 1991) 
CD34+ 154 X   (Solary et al., 1992) 
CD34+ 126 X   (Lee et al., 1992) 
CD34+ 38 X  
 (Myint and Lucie, 
1992) 
CD34+ 150 X   (Campos et al., 1992) 
CD34+ 70  X  (Selleri et al., 1992) 
CD34+ 80  X  (Ciolli et al., 1993) 
CD34+ 60 X   (Fagioli et al., 1993) 
CD34+ 52 X  
 (te Boekhorst et al., 
1993) 
CD34+ 62  X  (Lamy et al., 1994) 
CD34+ 168  X  (Bradstock et al., 1994) 
CD34+ 481  X  (Sperling et al., 1995) 
CD34+ 99  X  (Fruchart et al., 1996) 
CD34+ 42  X  (Arslan et al., 1996) 
CD34+ 517  X 
 (Porwit-MacDonald et 
al., 1996) 
CD34+ 62 X   (Dalal et al., 1997) 
CD34+ 141 X   (Raspadori et al., 1997) 
CD34+ 37 X   (Kyoda et al., 1998) 
CD34+ 783 X   (Repp et al., 2003) 
CD38- 325  X  (Koehler et al., 1993) 
CD38- 442 X   (Keyhani et al., 2000) 
CD38- 783 X   (Repp et al., 2003) 
c-kit- 168  X  (Bradstock et al., 1994) 
c-kit- 152   X (Advani et al., 2008) 
HLA-DR- 96   X (Geller et al., 1990) 
HLA-DR- 154   X (Solary et al., 1992) 
HLA-DR- 168  X  (Bradstock et al., 1994) 
CD34+CD38− 92 X   (van Rhenen A. et al., 
2005) 
CD34+CD38− 42 X   (Ebinger et al., 2010) 
ALDH+ 65 X   (Ran et al., 2009) 
 
 
Table 1. Summary of results from immunohistological prognostic studies of LSC markers 
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3. Breast cancer  
3.a Identified breast CSC markers 
Breast cancer was the first solid tumor identified to have a population of tumor cells with an 
inherent highly tumorigenic quality. These cells were termed tumor propagating cells at the 
time, and are now more commonly known as breast CSCs. In 2003, Al-Hajj et al. performed 
experiments akin to the leukemia studies discussed above (Bonnet and Dick, 1997; Lapidot 
et al., 1994), and isolated sub-tumor cell populations based on cell surface marker expression 
(Al-Hajj et al., 2003). The group showed that as few as 102 CD24-/lowCD44+ breast tumor cells 
could re-capitulate the tumor with much of its original heterogeneity (Al-Hajj et al., 2003). 
The authors proposed that not all CD24-/lowCD44+ cells were CSCs but that the breast CD24-
/lowCD44+ population was enriched for CSCs. It was hypothesized that if additional breast 
CSC markers were identified it may be possible to isolate and even more highly tumorigenic 
cells and initiate a tumor in xenograft from only one cell. This led to the pursuit of the 
identification of additional markers, both cell surface and functional.  
Using the same functional marker approach previously employed for leukemia (Cheung et 
al., 2007), Ginestier et al. were the first to isolate CSCs from a solid tumor based on increased 
ALDH activity (Ginestier et al., 2007). The researchers showed that as few as 102 ALDH+ 
breast cancer cell isolated from patients could induce tumors in immunocompromised mice. 
Further, in a proof of principle experiment, the researchers isolated CD24-/lowCD44+ALDH+ 
breast cancer cells and were able to induce tumors in immunocompromised mice with as 
few as 20 injected cells. This experiment combining mulitple markers for the isolation of 
highly tumorigenic cells provided supportive evidence to the proposed hypothesis that 
identifying additional markers would lead to further enrichment of the CSC population. 
In another more recent approach using a functional markers to identify novel breast CSCs, 
Pece et al. isolated the human normal mammary stem cells (hNMSCs) from mammary 
reduction surgeries by retention of a lipophillic fluorescent dye, PKH26 (Pece et al., 2010). 
PKH26 stains quiescent cells, allowing for the isolation of relatively non-dividing cells from 
a mixed population of proliferating cells (Lanzkron et al., 1999). From these isolated putative 
stem cells, Pece et al. identified a unique gene expression signature, the hNMSC signature, 
and applied it to published breast cancer gene expression data sets (Pece et al., 2010). This 
analysis revealed that many of the genes upregulated in normal mammary stem cells were 
also upregulated in higher grade, aggressive breast cancers. When the authors picked a few 
of these upregulated genes (i.e.CD49+, DLL1high, DNERhigh) and used them as cell surface 
markers, they were able to identify and isolate a sub-population of highly tumorigenic 
cancer initiating cells from breast tumors. As such, PKH26 stain retention and 
CD49+DLL1highDNERhigh are the most recent breast CSC markers identified. Interestingly, 
CD49 is a previously known normal mammary stem cell marker, and DLL1 and DNER have 
been connected to normal stem cell function. 
3.b Breast CSC markers as prognostic indicators 
CSC quantification is a proposed prognostic indicator for breast cancer. Translating this to 
clinical application requires immunohistological methods for identification of CSCs in 
fixed tumor tissue and in this respect, the data is less convincing and is summarized in 
Table 2. First, for CD24-/lowCD44+ the published studies have been mixed. In 2005, 
Abraham et al. were the first to publish a study on the prognostic applicability of the then 
newly identified breast CSC markers (Abraham et al., 2005). The authors double stained 
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an archived panel of 122 fixed breast cancer patient tumor samples for the prevalence of 
CD24-/lowCD44+. They failed to find a correlation between increased abundance of these 
cells and tumor progression or worse outcome, but they did note a tendency towards the 
development of distant metastases (Abraham et al., 2005). Subsequently, in 2008, Honeth 
et al. stained a panel of 240 breast cancer patient samples for CD24-/lowCD44+ cells and 
found an association between basal-like and BRCA1 hereditary breast cancer and the 
presence of CD24-/lowCD44+ cells (Honeth et al., 2008). Also in 2008, Mylona et al. stained 
a panel of 155 fixed patient tumor samples and reported that the prevalence of CD24-
/lowCD44+ cells did not significantly correlate with worse prognosis. In fact, in 
disagreement with the CSC theory they found the opposite. Surprisingly, patient tumors 
with increased CD24-/lowCD44+ cells tended to manifest increased disease-free survival 
(Mylona et al., 2008).  
Cultured cell experiments indicate that CD24-/lowCD44+ breast cancer cells are relatively 
more resistant to currently used therapeutics (Phillips et al., 2006). This suggests that 
prevalence of CD24-/lowCD44+ cells in patient tumors is a potential measure of the 
susceptibility of breast cancer to certain therapeutics. If this hypothesis is true, then one 
would predict that post treatment, the percentage of these cells would increase as the overall 
bulk of the tumor is decreased. In a recent neoadjuvant immunohistological study of an 
archived panel of patient tumor samples before and after treatment, Aulmann et al. failed to 
show an increase in the frequency of CD24-/lowCD44+ cells post treatment (Aulmann et al., 
2010). In contrast, in a challenge to the theory CSC of the therapeutic resistance of these cells, 
the authors found that post treatment, the percentage of CD24-/lowCD44+ tumor cells 
decreased relative to pretreatment (Aulmann et al., 2010). Further, the prevalence of these 
cells in a tumor did not correlate with the patient’s response to treatment or eventual 
outcome (Aulmann et al., 2010). However, in agreement with results by Abraham et al. who 
noted that patient tumors with higher percentages of CD24-/lowCD44+ tumor cells tended to 
develop distant metastases (Abraham et al., 2005), Aulmann et al. reported that patient 
tumors with higher percentages of CD24-/lowCD44+  cells tended to develop bone metastases 
with greater frequency (Aulmann et al., 2010). 
The results from the above described immunohistological studies evaluating the prevalence 
of CD24-/lowCD44+ cells in breast tumors as a readout for predicting the relative 
aggressiveness of a breast cancer do not support their use as prognostic indicators. This is 
surprising considering that the prevalence of CD44+ cells alone in fixed breast tumor cells 
was discovered to be predictive of more aggressive disease long before CD44 was identified 
as CSC marker (Al-Hajj et al., 2003). CD44 is a recognized predictor of breast cancer tumor 
grade (a histoclinical assessment of tumor cells and accepted clinical prognostic indicator 
(Dalton et al., 2000)), where patients with tumor cells expressing higher levels of CD44 
membrane proteins have worse outcomes (Joensuu et al., 1993; Looi et al., 2006; McSherry et 
al., 2007). In light of the undisputed correlation between CD44+ tumors and worse outcome 
for breast cancer patients, it seems that at least employing CD44+ as a CSC marker agrees 
with the proposed role of CSC in mediating cancer progression. Where the hypothesis fails 
is in the inclusion of CD24 as a CSC marker. Perhaps the inclusion of CD24-/low as a criterion 
is not necessary and may be detrimental, at least from a diagnostic perspective. In fact, even 
prior to its use as a selection criterion for breast CSC isolation, increased (not decreased!) 
CD24 expression had been correlated with worse outcome for breast cancer patients 
(Athanassiadou et al., 2009; Kristiansen et al., 2003). 
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With the revelation that breast CSCs could also be identified by increased ALDH activity, 
expression of ALDH1A1 prevalence in breast cancer tumors was assessed for prognostic 
applicability (Ginestier et al., 2007). In this first analysis, ALDH1A1 expression was detected 
in only 30% of fixed breast cancer tumor samples (Ginestier et al., 2007). Immunohistological 
staining of 577 fixed tumor specimens revealed a significant correlation between ALDH1A1 
expression and higher tumor grade. While these patients also had worse outcome overall, 
ALDH1A1 positivity failed to correlate with cancer stage and metastasis at the time of 
diagnosis (Ginestier et al., 2007). Later, in contrast, for a rare highly aggressive form of 
breast cancer, inflammatory breast cancer (one to five percent of all breast cancers), Charafe-
Jauffret et al. found a significant correlation between ALDH1A1 expression and 
development of metastasis and worse outcome (Charafe-Jauffret et al., 2010).  However, 
despite this positive correlation with a rare breast cancer, others have failed to show a 
significant correlation with ALDH1A1 prevalence and higher tumor grade, metastasis, 
therapeutic resistance or outcome with breast cancer in general (Morimoto et al., 2009; 
Neumeister et al., 2010; Neumeister and Rimm, 2009; Resetkova et al., 2009). In 2009, 
Morimoto et al. double immunohistochemical stained a panel of 203 fixed breast cancer 
tumor sample for the prevalence of ALDH1A1 along with estrogen receptor (ER), Ki67 and 
HER2 receptor status (Morimoto et al., 2009). The authors failed to find a correlation 
between ALDH1A1 prevalence and metastasis, but did note a non-significant trend with 
higher grade tumors. As well, ALDH1A1+ tumors were more likely to be ER-, Ki67-, and 
HER2+ (Morimoto et al., 2009). Also in 2009, Resetkova et al. immunostained four panels of 
fixed breast cancer patient panels, an adjuvantly treated series of 245 samples, a 
neoadjuvantly treated series of 34 samples and two series of 58 and 44 ER-PR-HER2- 
carcinoma samples. ALDH1A1 expression correlated significantly with basal-like HER2+ 
cancers, but not with other important indicators like metastasis. Interestingly, this result for 
ALDH1A1 was similar to the study on CD24-/lowCD44+ prevalence published by Honeth et 
al. who described a similar correlation between basal like breast cancers and CD24-
/lowCD44+ abundance. This would suggest that there is an overlap between ALDH1A1+ and 
CD24-/lowCD44+ cells and supports the notion that both markers identify at least some of the 
same cell population (i.e. CSCs). The neoadjuvantly stained data set failed to show an 
enrichment of ALDH1A1+ cells post treatment, therefore not supporting the hypothesis that 
CSC population is resistant to currently employed therapeutics (Resetkova et al., 2009). 
Interestingly, however, the authors noted an increased expression of ALDH1A1+ in the 
stromal tissue post treatment, but overall higher expression in the stroma was associated 
with better outcomes. Most recently, Neumeister et al stained a panel of 639 breast cancer 
for ALDH1A1, CD44 and cytokeratin (Neumeister et al., 2010). While the prevalence of all 
three markers together was associated with worse outcome, staining the cohort of samples 
for ALDH1A1 alone failed to correlate with any of the prognostic indicators (e.g. tumor 
grade, lymph node metastasis), nor patient outcome (Neumeister et al., 2010). Overall, the 
published data does not lend strong support toward the prognostic potential of ALDH1A1 
or CD24-/lowCD44+. This has led to the suggestion that other breast CSC marker need to be 
identified, and has resulted in some scepticism as to the validity of the existing identified 
markers (Neumeister and Rimm, 2009). However, it is noted that when employed in 
combination, CD44 and ALDH1A1 prevalence did predict outcome for breast cancer 
patients (Neumeister et al., 2010), suggesting that the key may be using the CSC markers in 
combination. 
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CD24-/low 201   X (Kristiansen et 
al., 2003) 
CD24-/low 70   X (Athanassiadou 
et al., 2009) 
CD44+ 198 X   (Joensuu et al., 
1993) 
CD44+ 70 X   (Ozer et al., 
1997) 
CD44+ 152 X   (Bankfalvi et 
al., 1998) 
CD44+ 135 X   (Schneider et 
al., 1999) 
CD44+ 60 X   (Looi et al., 
2006) 
CD24-/lowCD44+ 122  X  (Abraham et 
al., 2005) 
CD24-/lowCD44+ 240  X  (Honeth et al., 
2008) 
CD24-/lowCD44+ 155   X (Mylona et al., 
2008) 
CD24-/lowCD44+ 50  X  (Aulmann et 
al., 2010) 
ALDH1A1+ 577 X   (Ginestier et al., 
2007) 
ALDH1A1+ 203  X  (Morimoto et 
al., 2009) 
ALDH1A1+ 381  X  (Resetkova et 
al., 2009) 
ALDH1A1+ 109 X   (Charafe-
Jauffret et al., 
2010) 
ALDH1A1+ 639  X  (Neumeister et 
al., 2010) 





Table 2. Summary of results from immunohistological prognostic studies of breast CSC 
markers 
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4. Brain cancer 
4.a Identified brain CSC markers 
Soon after breast CSCs were identified based on CD24-/lowCD44+ expression, similar studies 
conducted by Sing et al. identified a sub-tumor population of glioblastoma (most common 
brain cancer) cancer cells that were highly tumorigenic. As few as 102 glioblastoma cancer 
cells expressiong neural stem cell marker CD133+ (prominin 1) (Uchida et al., 2000) induced 
tumors in immunocompromised mice (Singh et al., 2003; Singh et al., 2004). In contrast to the 
CD133+ brain tumor cells, the CD133- cells did not induce tumors, even when 105 cells were 
injected in the mice (Singh et al., 2004). As well, CD133+ cells exhibited the self-renewal 
differentiation properties characteristic of CSCs (Singh et al., 2004). Interestingly, as 
discussed later, CD133 would become a prominent CSC marker used for the isolation of 
highly tumorigenic cells in a number of cancers. However, like in other cancers, additional 
markers have been explored for brain cancer as well. 
Again taking cues from discoveries made from normal neural stem cell research, Ogdent et 
al. and Tchoghandjian et al. found that glioblastoma CSCs could be identified by increased 
expression A2B5 (Ogden et al., 2008; Tchoghandjian et al., 2010). A2B5 is a ganglioside 
expressed specifically on the cell surface of neural progenitor cells (Nunes et al., 2003). 
Unexpectedly, CD133+ and A2B5+ potentially identify separate populations of brain tumor 
cells that do not necessarily overlap, in a patient dependant manner. This finding challenges 
the CSC theory, which predicts the existence of a cancer initiating tumor cell population that 
is identifiable based on a universally expressed combination of markers. 
In 2007, Barraud et al. found that stage-specific embryonic antigen 4 (SSEA4), a known cell 
surface pluripotent human embryonic stem cell marker could also be used to enrich for the 
neural stem cells (Barraud et al., 2007). Subsequently, Son et al. found that the same marker 
could be used to isolate brain tumor cells with the CSC phenotype (increased 
tumorigenicity, self-renewal/differentiation properties) (Son et al., 2009). Almost all patient 
samples tested contained a SSEA4+ population, in agreement with the CSC theory (Son et 
al., 2009). 
As of yet ALDH activity has not been explored as a marker for the isolation of brain CSCs. 
Given its applicability in a number of cancers (as discussed above and below), it would be 
surprising to find that it is not a relevant brain CSC marker. 
4b. Brain CSC markers as prognostic indicators 
There have been a number of studies addressing prognostic applicability of the first 
brain/glioblastoma CSC marker identified, CD133+ (summarized in Table 3).  First, in 2008, 
Zeppernick et al. performed immunohistochemical analysis on 95 patient glioma samples of 
varied tumor grade and histology (Zeppernick et al., 2008). The authors report that CD133+ 
prevalence and clustering was associated significantly with worse outcome and survival. 
Further, CD133+ was a risk factor for tumor regrowth and metastasis, independent of tumor 
grade. Later that year, Beier et al., quantified a set of 36 high grade oligodendroglial tumors 
(less than 10% of all neural cancers) for their CD133 positivity (Beier et al., 2008). The 
authors reported that CD133 prevalence was a more accurate predictor of worse outcome 
for the patients than histological grading. In another 2008 study, Pallini et al. analysed a 
cohort of 44 glioblastoma patient tumor samples for prevalence of CD133+ and Ki67+ cells 
(Pallini et al., 2008). While CD133+ expression alone failed to predict patient oucome, 
coexpression of CD133/Ki67 was a highly significant independent prognostic risk factor 
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with prevalence of CD133+Ki67+ tumor cells being correlative with quickened disease 
progression and poor clinical outcome. In 2008, Zhang et al. stained a panel of 125 low and 
high grade glioblastoma patient tumor samples for coexpression of CD133 and nestin 
(Zhang et al., 2008). The authors reported that CD133+nestin+ was associated with worse 
outcome and survival, and could potentially be used as independent prognostic indicators. 
Finally, in 2010, Sato et al. assessed if CD133+ prevalence was associated with spread of the 
cancer in glioblastoma (Sato et al., 2010). The authors assessed 26 patient samples (16 cases 
of which the disease had disseminated) and reported that CD133 expression was 
significantly higher in disseminated disease cases.  In summary, these studies agree that 
initial CD133 expression, especially when assessed in combination with an additional 
marker, is associated with more aggressive brain cancer and worse outcome. Therefore, the 
studies provide supportive evidence for the CSC theory postulation that CSCs are the 
initiators and mediators of cancers. We now await the results of studies evaluating the 
prognostic potential of the more recently discovered brain CSC markers (i.e. A2B5 and 
SSEA4) alone and in combination with CD133. 
Most recently, the effect of therapy on the CSC population has been evaluated. In 2010, 
Pallini et al. quantified the frequency of CD133 pre and post radiochemotherapy on 37 
paired glioblastoma patient samples (Pallini et al., 2010). In support of the CSC theory that 
proposes CSCs are resistant to currently employed therapeutics, the researchers noted a 
significant increase (average 4.6 fold) in CD133+ cells post treatment. However, their 
analysis further revealed that the increased CD133+ frequency post treatment was 
surprisingly associated with improved survival, not worse. The authors’ following 
experiments revealed that not all CD133+ cells quantified in the tumors were in actuality 
tumor cells. The non-tumor cell CD133+ population might potentially have confounded their 
assessment of CSC frequency pre and post treatment and the effect on patient survival 
(Pallini et al., 2010). Furthermore, this revelation that not all CD133+ cells are tumor cells 
may explain their earlier results where CD133+ alone did not predict patient outcome, but 
CD133+Ki67+ did (Pallini et al., 2008). These results highlight the importance of employing 
multiple markers in the accurate identification of a CSC population in illustrating its 















CD133+ 95 X   
(Zeppernick et al., 
2008) 
CD133+ 36 X   (Beier et al., 2008) 
CD133+ 44  X  (Pallini et al., 2008) 
CD133+ 26 X   (Sato et al., 2010) 
CD133+ 37   X (Pallini et al., 2010) 
CD133+Ki67+ 44 X   (Pallini et al., 2008) 
CD133+nestin+ 125 X   (Zhang et al., 2008) 
Table 3. Summary of results from immunohistological prognostic studies of brain CSC 
markers 
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5. Colon cancer 
5.a Identified colon CSC markers 
In early 2007, two groups identified a small percentage of highly tumorigenic CD133+ colon 
cancer (colorectal carcinoma) with the renewal/differentiation properties of CSCs (O'Brien 
et al., 2007; Ricci-Vitiani et al., 2007). Ricci-Vitiani et al. estimated that CD133+ tumor cells 
made up 2.5% of total colon tumor cells, and O’Brien further calculated that only 1 in 
approximately 57,000 colon cancer cells was a CSC, but 1 in 262 CD133+ colon cancer cells 
was a CSC. Therefore while CD133 was one potential colon CSC marker, there remained 
others to be identified for the further enrichment of the CSC population. The following year, 
Shmelkov et al., reported that colon cancer initiating cells (CSCs) were found in both 
CD133+ and CD133- tumor cell populations, high-lighting the importance of identifying 
additional markers (Shmelkov et al., 2008). 
Dalerba et al., successfully identified and isolated colon CSCs based on expression of cell 
surface molecules other than CD133 (Dalerba et al., 2007). The researchers showed that 
EpCAM+CD44+ colon cancer cells ranged from 0.03% to 38% (mean = 5.4%) of total colon 
cancer cells and were highly tumorigenic in immunocompromised mice. In addition, the 
authors identified another cell surface adhesion molecule, CD166, which could be used for 
the isolation of colon CSCs. CD166 could be used independently of EpCAM/CD44 or 
synergistically with these other two markers to further enrich for the CSC population. In 
2008, Haraguchi et al. reported that CD133+ colon cancer varied in frequency from 0.3 – 
82.5% (mean 35.5%) and that the cancer initiating cell could be further enriched for by 
isolating cells that were positive for both CD133 and CD44 (Haraguchi et al., 2008). 
CD133+CD44+ colon cells were more tumorigenic than CD133+ or CD44+ isolated colon 
cancer cells. Interestingly, in 2009 another group showed that CD44+ isolated colon cells 
were highly tumorigenic, but failed to show similar tumorigenicity results when CD133 was 
used as the selection criterion (Chu et al., 2009).   
Spheroid cultured colon CSCs were analysed for their celluar antigen expression profile and 
were found to be positive for CD133, CD166, CD44, CD29, CD24, Lgr5 and nuclear β-catenin 
(Vermeulen et al., 2008). All of these were previously known as normal colon stem cell 
markers, and some had been previously identified as colon CSC markers. The authors 
further showed that cells identified as CD133+CD24+ were further enriched for CSCs, but 
that co-expression of the other identified cell surface markers (CD44, CD166, or CD29) with 
CD133 failed to further enrich for the CSC population. 
With the identification that ALDH activity could be used to isolate breast CSCs (Ginestier et 
al., 2007), ALDH activity was also assessed as a CSC marker for other solid tumors, 
including colon cancer. Colon cancer cells isolated based on increased ALDH activity by the 
aldefluor assay were shown to be more tumorigenic by a number of groups (Carpentino et 
al., 2009; Chu et al., 2009; Huang et al., 2009). Huang et al. first showed that as few as 25 
ALDH+ colon cancer cells could induce tumors in immunocompromised mice, and 
suggested that ALDH activity may be a more stringent selection marker than CD133 or 
CD44 for the selection of a colon CSC population (Huang et al., 2009). Undoubtedly, future 
studies will reveal if ALDH+ combined with expression of these cell surface molecules will 
lead to further enrichment of the colon CSC population. 
5.b Colon CSC markers as prognostic indicators 
The data evaluating the use of currently known colon CSC markers as prognostic indicators 
is mixed and summarized in Table 4. For example, CD133 expression analyses are plentiful 
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and do not reflect the molecule’s prognostic value. We will first review the positive studies. 
In 2008, Horst et al. performed an immunohistological study of 77 fixed patient tumor samples 
and found that increased CD133 expression was indicative of worse outcome for patients 
(Horst et al., 2008). Later in 2009, the same group assessed if expression of CD133 combined 
with β-catenin had significant prognostic value in a panel of 162 patient samples (Horst et al., 
2009a). CD133 and b-catenin stained distinct, partially overlapping cell populations and 
increased percentages of CD133+b-catenin+ was a stronger predictor of poor outcome than 
either marker alone (Horst et al., 2009a). The same group also compared the prognostic value 
of colon CSC markers CD133, CD44 and CD166 together and alone in a panel of 110 colorectal 
adenocarcinomas (Horst et al., 2009b). CD133 had the best prognostic potential of the three 
markers and correlated significantly with worse outcome (Horst et al., 2009b). However, 
patients with increased CD133+CD44+CD166+ tumor cells fared the worse, illustrating again 
the value of using the markers in combination. In a study by another group, CD133 expression 
was quantified in 189 colorectal carcinomas and was predictive of worse outcome when 
specified to patients with well- and moderately-differentiated adenocarcinomas (Kojima et al., 
2008). In a final example, increased CD133 expression in a panel of 104 stage IIIB colon 
carcinoma patient samples correlated with worse prognosis (Li et al., 2009). 
In contrast to above described positive results, Choi et al. performed immunohistological 
assessments on 523 patient samples, that represented the complete range of histoclinical 
diagnoses, to determine the prognostic value of colon CSC markers CD133, CD44 and CD24 
(Choi et al., 2009).  Interestingly while expression of CD adhesion molecules correlated with 
some of the histoclinical prognostic indicators, none were significant prognostic predictors 
of survival (Choi et al., 2009), disagreeing with the findings of Horst et al. (Horst et al., 2008; 
Horst et al., 2009a; Horst et al., 2009b). Specifically, the authors determined that CD133 
expression correlated with stage, CD24 with degree of differentiation and CD44 with tumor 
size (Choi et al., 2009). In 2010, Lugli et al., failed to correlate increased CD133 expression 
with tumor progression or survival time of patients when they probed a large panel of 1420 
colorectal cancers by tissue microarray (Lugli et al., 2010). The cohort of samples was also 
probed for other implicated colon CSC markers; CD166, CD44 and EpCAM, and in 
contradiction of the CSC theory, their loss of expression, not gain, was associated with 
increased tumor progression and survival time. This trend was even more evident when the 
markers were combined (e.g. CD166-CD44-).  
Independent of the discoveries implicating CD44, CD166, and CD24 as potential colon CSC 
markers (Dalerba et al., 2007; Vermeulen et al., 2008), the expression of the CD molecules 
has been previously assessed for predicting the outcome for colorectal cancer patients. For 
example, expression of certain splice variants of CD44 has been associated with worse 
outcome for colorectal cancer patients as early as the 1990s. In 1994, Mulder et al., stained 64 
patient panel samples and for CD44v6 reported that increased expression of the CD variant 
was associated with increased tumor-related death (Mulder et al., 1994). However, another 
study by Weg-Remers et al., failed to detect a correlation between expression of CD44, 
standard or variants, and patient outcome or tumor progression (Weg-Remers et al., 1998). 
CD166 expression had been associated with reduced survival, despite not being correlative 
with tumor grade, stage or nodal involvement (Weichert et al., 2004). The same group later 
stained a cohort of 147 colon cancer patient samples for CD24 expression and made the 
distinction between membrane and cytoplasmic CD24 (Weichert et al., 2005). Interestingly, 
patients with high levels of cyoplasmic CD24 fared significantly worse, being more likely to 
have higher grade tumors, and develop metastases. 
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CD133+ 77 X   
(Horst et al., 
2008) 
CD133+ 189 X   
(Kojima et al., 
2008) 
CD133+ 110 X   
(Horst et al., 
2009b) 
CD133+ 523  X  
(Choi et al., 
2009) 
CD133+ 104 X   
(Li et al., 
2010a) 
CD133+ 1420  X  
(Lugli et al., 
2010) 
CD24+ 147 X   
(Weichert et 
al., 2005) 
CD24+ 523  X  
(Choi et al., 
2009) 
CD44+ 83  X  
(Weg-Remers 
et al., 1998) 
CD44+ 110  X  
(Horst et al., 
2009b) 
CD44+ 523  X  
(Choi et al., 
2009) 
CD44+ 1420   X 
(Lugli et al., 
2010) 
CD166+ 111 X   
(Weichert et 
al., 2004) 
CD166+ 110  X  
(Horst et al., 
2009b) 
CD166+ 1420   X 
(Lugli et al., 
2010) 
EpCam+ 1420   X 
(Lugli et al., 
2010) 
CD166+CD44+ 1420   X 
(Lugli et al., 
2010) 
CD133+b-catenin+ 162 X   
(Horst et al., 
2009a) 
CD133+CD44+CD166+ 110 X   
(Horst et al., 
2009b) 
ALDH1A1+ 1420  X  
Lugli, 2010 442 
/id} 
 
Table 4. Summary of results from immunohistological prognostic studies of colon CSC 
markers 
www.intechopen.com
 Cancer Stem Cells Theories and Practice 
 
348 
Our analysis of the literature reveals a large disparity in the prognostic potential of the 
identified cell surface colon CSC markers. Potentially, differences in the results between 
groups could be explained by the varied methods and cut-offs used in tissue staining and 
scoring (Zlobec et al., 2007). For example Choi et al. scored the stained tissue samples as 
either positive or negative for expression of the CD molecules, whereas in the studies by 
Horst et al., the degree of staining was graded as none, low or high (Choi et al., 2009; Horst 
et al., 2008; Horst et al., 2009a; Horst et al., 2009b). Undoubtedly however, this can only be 
part of the explanation and it is more likely that the disagreement between groups is 
potentially an indication of the overall insignificant or poor prognostic value of these CSC 
markers for colon cancer when employed alone. 
With the 2009 discovery that ALDH activity is also specific to colon CSCs (Carpentino et al., 
2009; Chu et al., 2009; Huang et al., 2009), the potential of ALDH1A1 as a prognostic 
indicator is also being evaluated. In the recent study by Lugli et al., described above, who 
probed a panel of 1420 colorectal carcinomas for currently known cell surface colon CSC 
markers, the authors also assessed if ALDH1A1 expression had prognostic value (Lugli et 
al., 2010). The researchers detected ALDH1A1 in less than 25% of samples and failed to 
correlate patient outcome or disease progression with expression of the protein. Increased 
ALDH1A1 expression did however correlate with tumor grade (Lugli et al., 2010). In the 
coming years, the results of more immunohistological studies will clarify the potential 
prognostic power of ALDH1A1 for colorectal cancer. 
6. Prostate cancer 
6.a Identified prostate CSC markers 
The currently known prostate CSC markers are based on the unique cell surface molecules and 
functional characteristics of normal prostate stem cells. Combining previously identified 
prostate stem cell markers CD44+, α2β1high, CD133+, Collins et al. isolated prostate cancer cells 
from patient tumor samples that had the in vitro self-renewal and differentiation properties of 
CSCs (Collins et al., 2005). Later in 2006, Patrawala isolated CD44+ prostate cancer cells from 
cultures and tumors and showed that these cells possessed increased tumorigenicity in vivo 
and had stem cell like qualities (Patrawala et al., 2006).  In 2005, using a murine prostate cancer 
model, Xin et al. showed that prostate cancer cells expressing stem cell antigen-1 (sca-1) were 
comparatively highly tumorigenic and possessed stem cell like characteristic (Xin et al., 2005). 
More recently, ALDH activity was also explored as a CSC marker for prostate cancer (Li et al., 
2010b; van den Hoogen et al., 2010). Prostate cancer cells with increased ALDH activity were 
highly tumorigenic and possessed stem cell like characteristics (Li et al., 2010b; van den 
Hoogen et al., 2010). Interestingly, ALDH+ cancer cells were also positive for CD44 and α2β1 
integrin, but not CD133 (van den Hoogen et al., 2010). 
6.b Prostate CSC markers as prognostic indicators 
The prognostic potential of currently known prostate CSC markers is ambiguous at best at 
this time (summarized in Table 5). CD44 has been assessed as a prognostic marker for 
prostate cancer since the 1990’s, long before it was identified as a prostate CSC marker 
(Patrawala et al., 2006). In 1996, Nagabhushan et al. quantified the prevalence of CD44 in 74 
fixed prostate cancer patient samples and noted that CD44 expression correlated inversely 
with tumor grade (Nagabhushan et al., 1996). A similar inverse relationship was detected in 
a subsequent study (Noordzij et al., 1997). Then again, 1999 and 2000, the same group 
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published that CD44 expression decreased in patients with metastatic disease (Noordzij et 
al., 1999) and the loss of CD44 expression was an independent prognostic predictor of 
clinical reoccurrence (Vis et al., 2000). In 2001, Aaltomaa et al. analysed 209 prostate cancer 
samples and found that decreased CD44 expression correlated with metastasis and worse 
outcome (Aaltomaa et al., 2001). The results of these studies are in clear agreement with the 
prognostic potential of CD44 for prostate cancer. Unfortunately, from a CSC point of view, 
they are opposite to the predictions of the CSC theory, whereby an increase in CD44 would 
be expected to be associated with worse, not better outcomes.  
The recent discoveries that ALDH activity could be employed to isolate prostate CSCs were 
also accompanied by prognostic data. van den Hoogen et al., failed to detect ALDH1A1 in 
30 tissue microarray samples and 10 fixed primary tumor samples (van den Hoogen et al., 
2010). The authors then decided to evaluate if expression of some of the other ALDH 
isoforms correlated significantly with clinical pathological determinants. While expression 
of isoform ALDH7a1 was detected in the majority patient samples, its expression failed to 
correlate significantly with Gleason score or tumor grade. These findings are in contrast to 
results published by Li et al. who report that increased ALDH1A1 expression correlated 
significantly with Gleason score, disease stage, and worse survival (Li et al., 2010b). Future 
immunohistological studies should resolve the discrepancy between the two groups with 
regards to the prognostic importance of ALDH1A1.  
The greater prognostic potential of employing the CSC markers in combination remains to 
be shown for prostate cancer. Collins et al. who first discovered that the approximate 0.1%of 
CD44+α2β1highCD133+ of all prostate tumor cells had stem cell like characteristics, also 
reported that prevalence of these potential CSCs did not correlate with tumor grade (Collins 
et al., 2005). Perhaps future studies combining cell surface and functional markers (e.g. 
ALDH activity) may reveal a potential prognostic role for prostate CSC markers. 
 
Prognostic correlation 











CD44+ 74   X 
(Nagabhushan 
et al., 1996) 
CD44+ 97   X 
(Noordzij et al., 
1997) 
CD44+ 46   X 
(Noordzij et al., 
1999) 
CD44+ 209   X 
(Aaltomaa et 
al., 2001) 
CD44+α2β1highCD133+ 40  X  (Collins et al., 
2005) 
ALDH1A1+ 40  X  
(van den 
Hoogen et al., 
2010) 
ALDH1A1+ 163 X   (Li et al., 2010b) 
Table 5. Summary of results from immunohistological prognostic studies of prostate CSC 
markers 
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7. Lung cancer 
7.a Identified lung CSC markers 
Initially, a side population (SP) of lung cancer cells identified by exclusion of Hoechst 33342 
stain were shown to have stem cell like characteristics and overexpression of ABC 
transporters like ABCG2 was thought to mediate the innate chemo-resistance of stem cells 
(Hirschmann-Jax et al., 2004). The findings suggested the potential presence of a CSC 
population in lung cancer. Later, In 2008, Chen et al. isolated CD133+ and - cancer cell 
populations from lung cancer cell lines and non-small cell lung cancer patients and reported 
that CD133+ lung cancer cells had in vitro CSC and stem cell like qualities (Chen et al., 2008). 
This work provided the first indication that CD133 could potentially be used as a lung CSC 
marker. Later in 2009, Bertolini et al. proved that CD133 was a lung CSC marker (Bertolini et 
al., 2009).  The researchers showed that patient isolated CD133+ (and stained with epithelial-
specific antigen to eliminate contaminating cells) lung cancer cells were highly tumorigenic 
compared to CD133- cancer cells and had stem cell characteristics (Bertolini et al., 2009). 
Similar results using CD133 as a lung CSC marker were published by another group later 
that year, solidifying CD133’s recognition as an important lung CSC marker (Tirino et al., 
2009). 
ALDH activity has also been tested for the isolation of lung CSCs (Jiang et al., 2009; Ucar et 
al., 2009). Jiang et al. showed it was possible to isolate ALDH+ lung cancer cells from 
cultured cell lines that were more tumorigenic in immunocompromised mice and displayed 
stem cell like qualities (i.e. self renewal/differentiation and resistance to 
chemotherapeutics). As of yet ALDH activity and CD133 have not been employed in 
combination to potentially isolate a further CSC-encriched population of cells. 
7.b Lung CSC markers as prognostic indicators 
The data evaluating the use of currently known lung CSC markers as prognostic indicators 
is mixed and summarized in Table 6. In addition to illustrating the increased tumorigenicity 
of CD133+ lung cancer cells, Bertolini et al., assessed if CD133 had prognostic value for lung 
cancer patients (Bertolini et al., 2009). The researchers stained a panel of 42 fixed tumor 
samples for CD133 expression and showed that patients with CD133+ tumors tended to 
have a shorter progression-free survival. However, the outcome difference between CD133+ 
and CD133- tumors was not statistically significant. Tirino et al. also evaluated the 
prognostic potential of CD133 for lung cancer (Tirino et al., 2009). Their study of 89 patient 
samples failed to find a correlation between CD133 expression and the clinical pathological 
assessments of disease aggressiveness (e.g. tumor size, stage). However they noted a non-
significant trend toward shorter disease progression times in the CD133+ patient samples. In 
a another study of 88 patient samples conducted by Salnikov et al., CD133+ prevalence failed 
to significantly correlate with tumor size, cancer stage, local metastasis or overall survival 
(Salnikov et al., 2010).  Potentially if a larger sample size was employed in the studies 
statistical significance may have been reached for some parameters.   
The above studies suggest that presence of CD133 alone does not appear to be a strong 
predictor of disease progression and outcome for lung cancer. However, recent studies 
employing CD133 in combination with other markers appear more promising. In 2010, Li et 
al. showed that combination of CD133 with the ABC transporter, ABCG2, was a much more 
powerful prognostic tool than either marker alone (Li et  al., 2010a). The researchers stained 
a panel of 145 lung cancer patient samples, and when used alone neither marker correlated 
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significantly with clinical pathological assessment of disease or disease progression. 
However, when the prevalence of CD133+ABCG2+ was quantified, increased frequency of 
CD133+ABCG2+ cancer cells correlated significantly with shorter times to reoccurrence, 
illustrating the prognostic power of combining CSC markers. 
Finally with their recent discovery that ALDH activity could be employed to isolate lung 
CSCs, Jiang et al. also determined if ALDH1A1 positivity in lung cancer patient samples was 
a potential prognostic indicator (Jiang et al., 2009). ALDH1A1 expression correlated 
significantly with higher tumor grade, disease stage and poor clinical outcome (Jiang et al., 
2009). Interestingly, in these immunohistochemical analyses ALDH1A1 positive samples 
were also CD133+ (60% of patient samples). In contrast, patient samples that were negative 
for ALDH1A1 expression also lacked CD133 expression. This suggests that potentially 
CD133+ and ALDH+ can be combined to isolate a more tumorigenic population of lung 
cancer cells. Future studies will reveal if CD133 combined with ALDH1A1 is a superior and 
potentially powerful prognostic tool for lung cancer.  
 
Prognostic correlation 











CD133+ 42  X  
(Bertolini et al., 
2009) 
CD133+ 89  X  
(Tirino et al., 
2009) 
CD133+ 88  X  
(Salnikov et al., 
2010) 
CD133+ 145  X  (Li et al., 2010a) 
ABCG2+ 145  X  (Li et al., 2010a) 
CD133+ABCG2+ 145 X   (Li et al., 2010a) 
ALDH1A1+ 60 X   
(Jiang et al., 
2009) 
Table 6. Summary of results from immunohistological prognostic studies of lung CSC 
markers 
8. Conclusions 
CSCs have become a universal cancer concept. Using in vitro and in vivo experimental 
models, this sub-population of highly tumorigenic tumor cells has been shown to exist in 
most cancers and is resistant to chemo- and radiation therapy. As such, CSCs are believed to 
be the initiators of cancer, propagators of metastasis and mediators of therapeutic resistance. 
What is needed is conclusive proof of the importance of CSCs from clinical patient data. As 
reviewed here, there already exists much clinical data that support or refute the CSC theory 
from a cancer progression and reoccurrence point of view. Based on publised data thus far, 
it appears that using a combination of CSC markers, and eliminating the least relevant 
proposed CSC markers, is the most logical approach not only for accurate identification of 
CSCs but also for revelation of their important roles in cancer development. With the 
inevitable future discovery of new CSC markers and their combined use with valid ones 
previously discovered, the empirical proof that CSCs are the key to both the cause and cure 
of cancer may be a foregone conclusion. 
www.intechopen.com




Aaltomaa,S., Lipponen,P., la-Opas,M., and Kosma,V.M. (2001). Expression and prognostic 
value of CD44 standard and variant v3 and v6 isoforms in prostate cancer. Eur. 
Urol. 39, 138-144. 
Abraham,B.K., Fritz,P., McClellan,M., Hauptvogel,P., Athelogou,M., and Brauch,H. (2005). 
Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with 
clinical outcome but may favor distant metastasis. Clin. Cancer Res 11, 1154-1159. 
Advani,A.S., Rodriguez,C., Jin,T., Jawde,R.A., Saber,W., Baz,R., Kalaycio,M., Sobecks,R., 
Sekeres,M., Tripp,B., and Hsi,E. (2008). Increased C-kit intensity is a poor 
prognostic factor for progression-free and overall survival in patients with newly 
diagnosed AML. Leuk. Res. 32, 913-918. 
Al-Hajj,M., Wicha,M.S., ito-Hernandez,A., Morrison,S.J., and Clarke,M.F. (2003). Prospective 
identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. U. S. A 100, 
3983-3988. 
Armstrong,L., Stojkovic,M., Dimmick,I., Ahmad,S., Stojkovic,P., Hole,N., and Lako,M. 
(2004). Phenotypic characterization of murine primitive hematopoietic progenitor 
cells isolated on basis of aldehyde dehydrogenase activity. Stem Cells 22, 1142-1151. 
Arslan,O., Akan,H., Beksac,M., Ozcan,M., Koc,H., Ilhan,O., Konuk,N., and Uysal,A. (1996). 
Lack of prognostic value of CD34 in adult AML. Leuk. Lymphoma 23, 185-186. 
Athanassiadou,P., Grapsa,D., Gonidi,M., Athanassiadou,A.M., Tsipis,A., and Patsouris,E. 
(2009). CD24 expression has a prognostic impact in breast carcinoma. Pathol. Res. 
Pract. 205, 524-533. 
Aulmann,S., Waldburger,N., Penzel,R., Andrulis,M., Schirmacher,P., and Sinn,H.P. (2010). 
Reduction of CD44(+)/CD24(-) breast cancer cells by conventional cytotoxic 
chemotherapy. Hum. Pathol. 41, 574-581. 
Bankfalvi,A., Terpe,H.J., Breukelmann,D., Bier,B., Rempe,D., Pschadka,G., Krech,R., and 
Bocker,W. (1998). Gains and losses of CD44 expression during breast carcinogenesis 
and tumour progression. Histopathology 33, 107-116. 
Barraud,P., Stott,S., Mollgard,K., Parmar,M., and Bjorklund,A. (2007). In vitro 
characterization of a human neural progenitor cell coexpressing SSEA4 and CD133. 
J. Neurosci. Res. 85, 250-259. 
Beier,D., Wischhusen,J., Dietmaier,W., Hau,P., Proescholdt,M., Brawanski,A., Bogdahn,U., 
and Beier,C.P. (2008). CD133 expression and cancer stem cells predict prognosis in 
high-grade oligodendroglial tumors. Brain Pathol. 18, 370-377. 
Bertolini,G., Roz,L., Perego,P., Tortoreto,M., Fontanella,E., Gatti,L., Pratesi,G., Fabbri,A., 
Andriani,F., Tinelli,S., Roz,E., Caserini,R., Lo,V.S., Camerini,T., Mariani,L., Delia,D., 
Calabro,E., Pastorino,U., and Sozzi,G. (2009). Highly tumorigenic lung cancer 
CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc. 
Natl. Acad. Sci. U. S. A 106, 16281-16286. 
Blair,A., Hogge,D.E., Ailles,L.E., Lansdorp,P.M., and Sutherland,H.J. (1997). Lack of 
expression of Thy-1 (CD90) on acute myeloid leukemia cells with long-term 
proliferative ability in vitro and in vivo. Blood 89, 3104-3112. 
Blair,A., Hogge,D.E., and Sutherland,H.J. (1998). Most acute myeloid leukemia progenitor 
cells with long-term proliferative ability in vitro and in vivo have the phenotype 
CD34(+)/CD71(-)/HLA-DR-. Blood 92, 4325-4335. 
www.intechopen.com
The Rocky Road from Cancer Stem Cell Discovery to Diagnostic Applicability   
 
353 
Blair,A. and Sutherland,H.J. (2000). Primitive acute myeloid leukemia cells with long-term 
proliferative ability in vitro and in vivo lack surface expression of c-kit (CD117). 
Exp. Hematol. 28, 660-671. 
Bonnet,D. and Dick,J.E. (1997). Human acute myeloid leukemia is organized as a hierarchy 
that originates from a primitive hematopoietic cell. Nat. Med. 3, 730-737. 
Borowitz,M.J., Gockerman,J.P., Moore,J.O., Civin,C.I., Page,S.O., Robertson,J., and 
Bigner,S.H. (1989). Clinicopathologic and cytogenic features of CD34 (My 10)-
positive acute nonlymphocytic leukemia. Am. J. Clin. Pathol. 91, 265-270. 
Bradstock,K., Matthews,J., Benson,E., Page,F., and Bishop,J. (1994). Prognostic value of 
immunophenotyping in acute myeloid leukemia. Australian Leukaemia Study 
Group. Blood 84, 1220-1225. 
Campos,L., Guyotat,D., Archimbaud,E., Calmard-Oriol,P., Tsuruo,T., Troncy,J., Treille,D., and 
Fiere,D. (1992). Clinical significance of multidrug resistance P-glycoprotein 
expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood 79, 473-476. 
Campos,L., Guyotat,D., Archimbaud,E., Devaux,Y., Treille,D., Larese,A., Maupas,J., 
Gentilhomme,O., Ehrsam,A., and Fiere,D. (1989). Surface marker expression in 
adult acute myeloid leukaemia: correlations with initial characteristics, morphology 
and response to therapy. Br. J. Haematol. 72, 161-166. 
Carpentino,J.E., Hynes,M.J., Appelman,H.D., Zheng,T., Steindler,D.A., Scott,E.W., and 
Huang,E.H. (2009). Aldehyde dehydrogenase-expressing colon stem cells 
contribute to tumorigenesis in the transition from colitis to cancer. Cancer Res. 69, 
8208-8215. 
Charafe-Jauffret,E., Ginestier,C., Iovino,F., Tarpin,C., Diebel,M., Esterni,B., 
Houvenaeghel,G., Extra,J.M., Bertucci,F., Jacquemier,J., Xerri,L., Dontu,G., Stassi,G., 
Xiao,Y., Barsky,S.H., Birnbaum,D., Viens,P., and Wicha,M.S. (2010). Aldehyde 
dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical 
outcome in inflammatory breast cancer. Clin. Cancer Res. 16, 45-55. 
Chen,Y.C., Hsu,H.S., Chen,Y.W., Tsai,T.H., How,C.K., Wang,C.Y., Hung,S.C., Chang,Y.L., 
Tsai,M.L., Lee,Y.Y., Ku,H.H., and Chiou,S.H. (2008). Oct-4 expression maintained 
cancer stem-like properties in lung cancer-derived CD133-positive cells. PLoS. 
ONE. 3, e2637. 
Cheung,A.M., Wan,T.S., Leung,J.C., Chan,L.Y., Huang,H., Kwong,Y.L., Liang,R., and 
Leung,A.Y. (2007). Aldehyde dehydrogenase activity in leukemic blasts defines a 
subgroup of acute myeloid leukemia with adverse prognosis and superior 
NOD/SCID engrafting potential. Leukemia 21, 1423-1430. 
Choi,D., Lee,H.W., Hur,K.Y., Kim,J.J., Park,G.S., Jang,S.H., Song,Y.S., Jang,K.S., and Paik,S.S. 
(2009). Cancer stem cell markers CD133 and CD24 correlate with invasiveness and 
differentiation in colorectal adenocarcinoma. World J. Gastroenterol. 15, 2258-2264. 
Chu,P., Clanton,D.J., Snipas,T.S., Lee,J., Mitchell,E., Nguyen,M.L., Hare,E., and Peach,R.J. 
(2009). Characterization of a subpopulation of colon cancer cells with stem cell-like 
properties. Int. J. Cancer 124, 1312-1321. 
Chute,J.P., Muramoto,G.G., Whitesides,J., Colvin,M., Safi,R., Chao,N.J., and McDonnell,D.P. 
(2006). Inhibition of aldehyde dehydrogenase and retinoid signaling induces the 
expansion of human hematopoietic stem cells. Proc. Natl. Acad. Sci. U. S. A 103, 
11707-11712. 
www.intechopen.com
 Cancer Stem Cells Theories and Practice 
 
354 
Ciolli,S., Leoni,F., Caporale,R., Pascarella,A., Salti,F., and Rossi-Ferrini,P. (1993). CD34 
expression fails to predict the outcome in adult acute myeloid leukemia. 
Haematologica 78, 151-155. 
Collins,A.T., Berry,P.A., Hyde,C., Stower,M.J., and Maitland,N.J. (2005). Prospective 
identification of tumorigenic prostate cancer stem cells. Cancer Res 65, 10946-10951. 
Collins,S.J. (2008). Retinoic acid receptors, hematopoiesis and leukemogenesis. Curr. Opin. 
Hematol. 15, 346-351. 
Dalal,B.I., Wu,V., Barnett,M.J., Horsman,D.E., Spinelli,J.J., Naiman,S.C., Shepherd,J.D., 
Nantel,S.H., Reece,D.E., Sutherland,H.J., Klingemann,H.G., and Phillips,G.L. (1997). 
Induction failure in de novo acute myelogenous leukemia is associated with 
expression of high levels of CD34 antigen by the leukemic blasts. Leuk. Lymphoma 
26, 299-306. 
Dalerba,P., Dylla,S.J., Park,I.K., Liu,R., Wang,X., Cho,R.W., Hoey,T., Gurney,A., Huang,E.H., 
Simeone,D.M., Shelton,A.A., Parmiani,G., Castelli,C., and Clarke,M.F. (2007). 
Phenotypic characterization of human colorectal cancer stem cells. Proc. Natl. 
Acad. Sci. U. S. A 104, 10158-10163. 
Dalton,L.W., Pinder,S.E., Elston,C.E., Ellis,I.O., Page,D.L., Dupont,W.D., and Blamey,R.W. 
(2000). Histologic grading of breast cancer: linkage of patient outcome with level of 
pathologist agreement. Mod. Pathol. 13, 730-735. 
Ebinger,M., Witte,K.E., Ahlers,J., Schafer,I., Andre,M., Kerst,G., Scheel-Walter,H.G., Lang,P., 
and Handgretinger,R. (2010). High frequency of immature cells at diagnosis 
predicts high minimal residual disease level in childhood acute lymphoblastic 
leukemia. Leuk. Res. 34, 1139-1142. 
Fagioli,F., Cuneo,A., Carli,M.G., Bardi,A., Piva,N., Previati,R., Rigolin,G.M., Ferrari,L., 
Spanedda,R., and Castoldi,G. (1993). Chromosome aberrations in CD34-positive 
acute myeloid leukemia. Correlation with clinicopathologic features. Cancer Genet. 
Cytogenet. 71, 119-124. 
Fruchart,C., Lenormand,B., Bastard,C., Boulet,D., Lesesve,J.F., Callat,M.P., Stamatoullas,A., 
Monconduit,M., and Tilly,H. (1996). Correlation between CD34 expression and 
chromosomal abnormalities but not clinical outcome in acute myeloid leukemia. 
Am. J. Hematol. 53, 175-180. 
Geller,R.B., Zahurak,M., Hurwitz,C.A., Burke,P.J., Karp,J.E., Piantadosi,S., and Civin,C.I. 
(1990). Prognostic importance of immunophenotyping in adults with acute 
myelocytic leukaemia: the significance of the stem-cell glycoprotein CD34 (My10). 
Br. J. Haematol. 76, 340-347. 
Ginestier,C., Hur,M.H., Charafe-Jauffret,E., Monville,F., Dutcher,J., Brown,M., Jacquemier,J., 
Viens,P., Kleer,C.G., Liu,S., Schott,A., Hayes,D., Birnbaum,D., Wicha,M.S., and 
Dontu,G. (2007). ALDH1 Is a Marker of Normal and Malignant Human Mammary 
Stem Cells and a Predictor of Poor Clinical Outcome. Cell Stem Cell 1, 555-567. 
Guinot,M., Sanz,G.F., Sempere,A., Arilla,M.J., Jarque,I., Gomis,F., and Sanz,M.A. (1991). 
Prognostic value of CD34 expression in de novo acute myeloblastic leukaemia. Br. 
J. Haematol. 79, 533-534. 
Haraguchi,N., Ohkuma,M., Sakashita,H., Matsuzaki,S., Tanaka,F., Mimori,K., Kamohara,Y., 
Inoue,H., and Mori,M. (2008). CD133+CD44+ population efficiently enriches colon 
cancer initiating cells. Ann. Surg. Oncol. 15, 2927-2933. 
www.intechopen.com
The Rocky Road from Cancer Stem Cell Discovery to Diagnostic Applicability   
 
355 
Hirschmann-Jax,C., Foster,A.E., Wulf,G.G., Nuchtern,J.G., Jax,T.W., Gobel,U., Goodell,M.A., 
and Brenner,M.K. (2004). A distinct "side population" of cells with high drug efflux 
capacity in human tumor cells. Proc. Natl. Acad. Sci. U. S. A 101, 14228-14233. 
Honeth,G., Bendahl,P.O., Ringner,M., Saal,L.H., Gruvberger-Saal,S.K., Lovgren,K., 
Grabau,D., Ferno,M., Borg,A., and Hegardt,C. (2008). The CD44+/CD24- 
phenotype is enriched in basal-like breast tumors. Breast Cancer Res. 10, R53. 
Horst,D., Kriegl,L., Engel,J., Jung,A., and Kirchner,T. (2009a). CD133 and nuclear beta-
catenin: the marker combination to detect high risk cases of low stage colorectal 
cancer. Eur. J. Cancer 45, 2034-2040. 
Horst,D., Kriegl,L., Engel,J., Kirchner,T., and Jung,A. (2008). CD133 expression is an 
independent prognostic marker for low survival in colorectal cancer. Br. J. Cancer 
99, 1285-1289. 
Horst,D., Kriegl,L., Engel,J., Kirchner,T., and Jung,A. (2009b). Prognostic significance of the 
cancer stem cell markers CD133, CD44, and CD166 in colorectal cancer. Cancer 
Invest 27, 844-850. 
Huang,E.H., Hynes,M.J., Zhang,T., Ginestier,C., Dontu,G., Appelman,H., Fields,J.Z., 
Wicha,M.S., and Boman,B.M. (2009). Aldehyde dehydrogenase 1 is a marker for 
normal and malignant human colonic stem cells (SC) and tracks SC overpopulation 
during colon tumorigenesis. Cancer Res. 69, 3382-3389. 
Jiang,F., Qiu,Q., Khanna,A., Todd,N.W., Deepak,J., Xing,L., Wang,H., Liu,Z., Su,Y., 
Stass,S.A., and Katz,R.L. (2009). Aldehyde dehydrogenase 1 is a tumor stem cell-
associated marker in lung cancer. Mol. Cancer Res. 7, 330-338. 
Joensuu,H., Klemi,P.J., Toikkanen,S., and Jalkanen,S. (1993). Glycoprotein CD44 expression 
and its association with survival in breast cancer. Am. J. Pathol. 143, 867-874. 
Jordan,C.T., Upchurch,D., Szilvassy,S.J., Guzman,M.L., Howard,D.S., Pettigrew,A.L., 
Meyerrose,T., Rossi,R., Grimes,B., Rizzieri,D.A., Luger,S.M., and Phillips,G.L. 
(2000). The interleukin-3 receptor alpha chain is a unique marker for human acute 
myelogenous leukemia stem cells. Leukemia 14, 1777-1784. 
Kanda,Y., Hamaki,T., Yamamoto,R., Chizuka,A., Suguro,M., Matsuyama,T., Takezako,N., 
Miwa,A., Kami,M., Hirai,H., and Togawa,A. (2000). The clinical significance of 
CD34 expression in response to therapy of patients with acute myeloid leukemia: 
an overview of 2483 patients from 22 studies. Cancer 88, 2529-2533. 
Keyhani,A., Huh,Y.O., Jendiroba,D., Pagliaro,L., Cortez,J., Pierce,S., Pearlman,M., Estey,E., 
Kantarjian,H., and Freireich,E.J. (2000). Increased CD38 expression is associated 
with favorable prognosis in adult acute leukemia. Leuk. Res. 24, 153-159. 
Koehler,M., Behm,F., Hancock,M., and Pui,C.H. (1993). Expression of activation antigens 
CD38 and CD71 is not clinically important in childhood acute lymphoblastic 
leukemia. Leukemia 7, 41-45. 
Kojima,M., Ishii,G., Atsumi,N., Fujii,S., Saito,N., and Ochiai,A. (2008). Immunohistochemical 
detection of CD133 expression in colorectal cancer: a clinicopathological study. 
Cancer Sci. 99, 1578-1583. 
Kristiansen,G., Winzer,K.J., Mayordomo,E., Bellach,J., Schluns,K., Denkert,C., Dahl,E., 
Pilarsky,C., Altevogt,P., Guski,H., and Dietel,M. (2003). CD24 expression is a new 
prognostic marker in breast cancer. Clin. Cancer Res. 9, 4906-4913. 
Kyoda,K., Nakamura,S., Hattori,N., Takeshima,M., Nakamura,K., Kaya,H., Matano,S., 
Okumura,H., Kanno,M., Ohtake,S., and Matsuda,T. (1998). Lack of prognostic 
www.intechopen.com
 Cancer Stem Cells Theories and Practice 
 
356 
significance of CD34 expression in adult AML when FAB M0 and M3 are excluded. 
Am. J. Hematol. 57, 265-266. 
Lamy,T., Goasguen,J.E., Mordelet,E., Grulois,I., Dauriac,C., Drenou,B., Chaperon,J., 
Fauchet,R., and le Prise,P.Y. (1994). P-glycoprotein (P-170) and CD34 expression in 
adult acute myeloid leukemia (AML). Leukemia 8, 1879-1883. 
Lanzkron,S.M., Collector,M.I., and Sharkis,S.J. (1999). Hematopoietic stem cell tracking in 
vivo: a comparison of short-term and long-term repopulating cells. Blood 93, 1916-
1921. 
Lapidot,T., Sirard,C., Vormoor,J., Murdoch,B., Hoang,T., Caceres-Cortes,J., Minden,M., 
Paterson,B., Caligiuri,M.A., and Dick,J.E. (1994). A cell initiating human acute 
myeloid leukaemia after transplantation into SCID mice. Nature 367, 645-648. 
Lee,E.J., Yang,J., Leavitt,R.D., Testa,J.R., Civin,C.I., Forrest,A., and Schiffer,C.A. (1992). The 
significance of CD34 and TdT determinations in patients with untreated de novo 
acute myeloid leukemia. Leukemia 6, 1203-1209. 
Li,C.Y., Li,B.X., Liang,Y., Peng,R.Q., Ding,Y., Xu,D.Z., Zhang,X., Pan,Z.Z., Wan,D.S., 
Zeng,Y.X., Zhu,X.F., and Zhang,X.S. (2009). Higher percentage of CD133+ cells is 
associated with poor prognosis in colon carcinoma patients with stage IIIB. J. 
Transl. Med. 7, 56. 
Li,F., Zeng,H., and Ying,K. (2010a). The combination of stem cell markers CD133 and 
ABCG2 predicts relapse in stage I non-small cell lung carcinomas. Med. Oncol. 
Li,T., Su,Y., Mei,Y., Leng,Q., Leng,B., Liu,Z., Stass,S.A., and Jiang,F. (2010b). ALDH1A1 is a 
marker for malignant prostate stem cells and predictor of prostate cancer patients' 
outcome. Lab Invest 90, 234-244. 
Looi,L.M., Cheah,P.L., Zhao,W., Ng,M.H., and Yip,C.H. (2006). CD44 expression and 
axillary lymph node metastasis in infiltrating ductal carcinoma of the breast. 
Malays. J. Pathol. 28, 83-86. 
Lugli,A., Iezzi,G., Hostettler,I., Muraro,M.G., Mele,V., Tornillo,L., Carafa,V., Spagnoli,G., 
Terracciano,L., and Zlobec,I. (2010). Prognostic impact of the expression of putative 
cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal 
cancer. Br. J. Cancer 103, 382-390. 
Magni,M., Shammah,S., Schiro,R., Mellado,W., la-Favera,R., and Gianni,A.M. (1996). 
Induction of cyclophosphamide-resistance by aldehyde-dehydrogenase gene 
transfer. Blood 87, 1097-1103. 
Marchitti,S.A., Brocker,C., Stagos,D., and Vasiliou,V. (2008). Non-P450 aldehyde oxidizing 
enzymes: the aldehyde dehydrogenase superfamily. Expert. Opin. Drug Metab 
Toxicol. 4, 697-720. 
McSherry,E.A., Donatello,S., Hopkins,A.M., and McDonnell,S. (2007). Molecular basis of 
invasion in breast cancer. Cell Mol. Life Sci. 64, 3201-18. 
Morimoto,K., Kim,S.J., Tanei,T., Shimazu,K., Tanji,Y., Taguchi,T., Tamaki,Y., Terada,N., and 
Noguchi,S. (2009). Stem cell marker aldehyde dehydrogenase 1-positive breast 
cancers are characterized by negative estrogen receptor, positive human epidermal 
growth factor receptor type 2, and high Ki67 expression. Cancer Sci. 100, 1062-1068. 
Mulder,J.W., Kruyt,P.M., Sewnath,M., Oosting,J., Seldenrijk,C.A., Weidema,W.F., 
Offerhaus,G.J., and Pals,S.T. (1994). Colorectal cancer prognosis and expression of 
exon-v6-containing CD44 proteins. Lancet 344, 1470-1472. 
www.intechopen.com
The Rocky Road from Cancer Stem Cell Discovery to Diagnostic Applicability   
 
357 
Myint,H. and Lucie,N.P. (1992). The prognostic significance of the CD34 antigen in acute 
myeloid leukaemia. Leuk. Lymphoma 7, 425-429. 
Mylona,E., Giannopoulou,I., Fasomytakis,E., Nomikos,A., Magkou,C., Bakarakos,P., and 
Nakopoulou,L. (2008). The clinicopathologic and prognostic significance of 
CD44+/CD24(-/low) and CD44-/CD24+ tumor cells in invasive breast carcinomas. 
Hum. Pathol. 39, 1096-1102. 
Nagabhushan,M., Pretlow,T.G., Guo,Y.J., Amini,S.B., Pretlow,T.P., and Sy,M.S. (1996). 
Altered expression of CD44 in human prostate cancer during progression. Am. J. 
Clin. Pathol. 106, 647-651. 
Neumeister,V., Agarwal,S., Bordeaux,J., Camp,R.L., and Rimm,D.L. (2010). In situ 
identification of putative cancer stem cells by multiplexing ALDH1, CD44, and 
cytokeratin identifies breast cancer patients with poor prognosis. Am. J. Pathol. 176, 
2131-2138. 
Neumeister,V. and Rimm,D. (2010). Is ALDH1 a good method for definition of breast cancer 
stem cells? Breast Cancer Res. Treat. 123, 109-11. 
Noordzij,M.A., van Steenbrugge,G.J., Schroder,F.H., and van der Kwast,T.H. (1999). 
Decreased expression of CD44 in metastatic prostate cancer. Int. J. Cancer 84, 478-
483. 
Noordzij,M.A., van Steenbrugge,G.J., Verkaik,N.S., Schroder,F.H., and van der Kwast,T.H. 
(1997). The prognostic value of CD44 isoforms in prostate cancer patients treated by 
radical prostatectomy. Clin. Cancer Res. 3, 805-815. 
Nunes,M.C., Roy,N.S., Keyoung,H.M., Goodman,R.R., McKhann,G., Jiang,L., Kang,J., 
Nedergaard,M., and Goldman,S.A. (2003). Identification and isolation of 
multipotential neural progenitor cells from the subcortical white matter of the adult 
human brain. Nat. Med. 9, 439-447. 
O'Brien,C.A., Pollett,A., Gallinger,S., and Dick,J.E. (2007). A human colon cancer cell capable 
of initiating tumour growth in immunodeficient mice. Nature 445, 106-110. 
Ogden,A.T., Waziri,A.E., Lochhead,R.A., Fusco,D., Lopez,K., Ellis,J.A., Kang,J., Assanah,M., 
McKhann,G.M., Sisti,M.B., McCormick,P.C., Canoll,P., and Bruce,J.N. (2008). 
Identification of A2B5+CD133- tumor-initiating cells in adult human gliomas. 
Neurosurgery 62, 505-514. 
Ozer,E., Canda,T., and Kurtodlu,B. (1997). The role of angiogenesis, laminin and CD44 
expression in metastatic behavior of early-stage low-grade invasive breast 
carcinomas. Cancer Lett. 121, 119-123. 
Pallini,R., Ricci-Vitiani,L., Banna,G.L., Signore,M., Lombardi,D., Todaro,M., Stassi,G., 
Martini,M., Maira,G., Larocca,L.M., and De,M.R. (2008). Cancer stem cell analysis 
and clinical outcome in patients with glioblastoma multiforme. Clin. Cancer Res. 
14, 8205-8212. 
Pallini,R., Ricci-Vitiani,L., Montano,N., Mollinari,C., Biffoni,M., Cenci,T., Pierconti,F., 
Martini,M., De,M.R., and Larocca,L.M. (2010). Expression of the stem cell marker 
CD133 in recurrent glioblastoma and its value for prognosis. Cancer. 
Patrawala,L., Calhoun,T., Schneider-Broussard,R., Li,H., Bhatia,B., Tang,S., Reilly,J.G., 
Chandra,D., Zhou,J., Claypool,K., Coghlan,L., and Tang,D.G. (2006). Highly 
purified CD44+ prostate cancer cells from xenograft human tumors are enriched in 
tumorigenic and metastatic progenitor cells. Oncogene 25, 1696-1708. 
www.intechopen.com
 Cancer Stem Cells Theories and Practice 
 
358 
Pece,S., Tosoni,D., Confalonieri,S., Mazzarol,G., Vecchi,M., Ronzoni,S., Bernard,L., Viale,G., 
Pelicci,P.G., and Di Fiore,P.P. (2010). Biological and molecular heterogeneity of 
breast cancers correlates with their cancer stem cell content. Cell 140, 62-73. 
Phillips,T.M., McBride,W.H., and Pajonk,F. (2006). The response of CD24(-/low)/CD44+ 
breast cancer-initiating cells to radiation. J. Natl. Cancer Inst. 98, 1777-1785. 
Porwit-MacDonald,A., Janossy,G., Ivory,K., Swirsky,D., Peters,R., Wheatley,K., Walker,H., 
Turker,A., Goldstone,A.H., and Burnett,A. (1996). Leukemia-associated changes 
identified by quantitative flow cytometry. IV. CD34 overexpression in acute 
myelogenous leukemia M2 with t(8;21). Blood 87, 1162-1169. 
Ran,D., Schubert,M., Pietsch,L., Taubert,I., Wuchter,P., Eckstein,V., Bruckner,T., Zoeller,M., 
and Ho,A.D. (2009). Aldehyde dehydrogenase activity among primary leukemia 
cells is associated with stem cell features and correlates with adverse clinical 
outcomes. Exp. Hematol. 37, 1423-1434. 
Raspadori,D., Lauria,F., Ventura,M.A., Rondelli,D., Visani,G., de,V.A., and Tura,S. (1997). 
Incidence and prognostic relevance of CD34 expression in acute myeloblastic 
leukemia: analysis of 141 cases. Leuk. Res. 21, 603-607. 
Repp,R., Schaekel,U., Helm,G., Thiede,C., Soucek,S., Pascheberg,U., Wandt,H., Aulitzky,W., 
Bodenstein,H., Sonnen,R., Link,H., Ehninger,G., and Gramatzki,M. (2003). 
Immunophenotyping is an independent factor for risk stratification in AML. 
Cytometry B Clin. Cytom. 53, 11-19. 
Resetkova,E., Reis-Filho,J.S., Jain,R.K., Mehta,R., Thorat,M.A., Nakshatri,H., and Badve,S. 
(2010). Prognostic impact of ALDH1 in breast cancer: a story of stem cells and 
tumor microenvironment. Breast Cancer Res. Treat. 123, 97-108. 
Ricci-Vitiani,L., Lombardi,D.G., Pilozzi,E., Biffoni,M., Todaro,M., Peschle,C., and De,M.R. 
(2007). Identification and expansion of human colon-cancer-initiating cells. Nature 
445, 111-115. 
Salnikov,A.V., Gladkich,J., Moldenhauer,G., Volm,M., Mattern,J., and Herr,I. (2010). CD133 
is indicative for a resistance phenotype but does not represent a prognostic marker 
for survival of non-small cell lung cancer patients. Int. J. Cancer 126, 950-958. 
Sato,A., Sakurada,K., Kumabe,T., Sasajima,T., Beppu,T., Asano,K., Ohkuma,H., Ogawa,A., 
Mizoi,K., Tominaga,T., Kitanaka,C., and Kayama,T. (2010). Association of stem cell 
marker CD133 expression with dissemination of glioblastomas. Neurosurg. Rev. 33, 
175-183. 
Schneider,J., Pollan,M., Ruibal,A., Jimenez,E., Lucas,A.R., Nunez,M.I., Sanchez,J., and 
Tejerina,A. (1999). Histologic grade and CD44 are independent predictors of 
axillary lymph node invasion in early (T1) breast cancer. Tumour. Biol. 20, 319-330. 
Selleri,C., Notaro,R., Catalano,L., Fontana,R., Del,V.L., and Rotoli,B. (1992). Prognostic 
irrelevance of CD34 in acute myeloid leukaemia. Br. J. Haematol. 82, 479-481. 
Shmelkov,S.V., Butler,J.M., Hooper,A.T., Hormigo,A., Kushner,J., Milde,T., St,C.R., 
Baljevic,M., White,I., Jin,D.K., Chadburn,A., Murphy,A.J., Valenzuela,D.M., 
Gale,N.W., Thurston,G., Yancopoulos,G.D., D'Angelica,M., Kemeny,N., Lyden,D., 
and Rafii,S. (2008). CD133 expression is not restricted to stem cells, and both 
CD133+ and C. J. Clin. Invest 118, 2111-2120. 
Singh,S.K., Clarke,I.D., Terasaki,M., Bonn,V.E., Hawkins,C., Squire,J., and Dirks,P.B. (2003). 
Identification of a cancer stem cell in human brain tumors. Cancer Res. 63, 5821-
5828. 
www.intechopen.com
The Rocky Road from Cancer Stem Cell Discovery to Diagnostic Applicability   
 
359 
Singh,S.K., Hawkins,C., Clarke,I.D., Squire,J.A., Bayani,J., Hide,T., Henkelman,R.M., 
Cusimano,M.D., and Dirks,P.B. (2004). Identification of human brain tumour 
initiating cells. Nature 432, 396-401. 
Solary,E., Casasnovas,R.O., Campos,L., Bene,M.C., Faure,G., Maingon,P., Falkenrodt,A., 
Lenormand,B., and Genetet,N. (1992). Surface markers in adult acute myeloblastic 
leukemia: correlation of CD19+, CD34+ and CD14+/DR--phenotypes with shorter 
survival. Groupe d'Etude Immunologique des Leucemies (GEIL). Leukemia 6, 393-
399. 
Son,M.J., Woolard,K., Nam,D.H., Lee,J., and Fine,H.A. (2009). SSEA-1 is an enrichment 
marker for tumor-initiating cells in human glioblastoma. Cell Stem Cell 4, 440-452. 
Sperling,C., Buchner,T., Creutzig,U., Ritter,J., Harbott,J., Fonatsch,C., Sauerland,C., 
Mielcarek,M., Maschmeyer,G., Loffler,H., and . (1995). Clinical, morphologic, 
cytogenetic and prognostic implications of CD34 expression in childhood and adult 
de novo AML. Leuk. Lymphoma 17, 417-426. 
Tchoghandjian,A., Baeza,N., Colin,C., Cayre,M., Metellus,P., Beclin,C., Ouafik,L., and 
Figarella-Branger,D. (2010). A2B5 cells from human glioblastoma have cancer stem 
cell properties. Brain Pathol. 20, 211-221. 
te Boekhorst,P.A., de,L.K., Schoester,M., Wittebol,S., Nooter,K., Hagemeijer,A., 
Lowenberg,B., and Sonneveld,P. (1993). Predominance of functional multidrug 
resistance (MDR-1) phenotype in CD34+ acute myeloid leukemia cells. Blood 82, 
3157-3162. 
Tirino,V., Camerlingo,R., Franco,R., Malanga,D., La,R.A., Viglietto,G., Rocco,G., and 
Pirozzi,G. (2009). The role of CD133 in the identification and characterisation of 
tumour-initiating cells in non-small-cell lung cancer. Eur. J. Cardiothorac. Surg. 36, 
446-453. 
Ucar,D., Cogle,C.R., Zucali,J.R., Ostmark,B., Scott,E.W., Zori,R., Gray,B.A., and Moreb,J.S. 
(2009). Aldehyde dehydrogenase activity as a functional marker for lung cancer. 
Chem. Biol. Interact. 178, 48-55. 
Uchida,N., Buck,D.W., He,D., Reitsma,M.J., Masek,M., Phan,T.V., Tsukamoto,A.S., 
Gage,F.H., and Weissman,I.L. (2000). Direct isolation of human central nervous 
system stem cells. Proc. Natl. Acad. Sci. U. S. A 97, 14720-14725. 
van den Hoogen,C., van der,H.G., Cheung,H., Buijs,J.T., Lippitt,J.M., Guzman-Ramirez,N., 
Hamdy,F.C., Eaton,C.L., Thalmann,G.N., Cecchini,M.G., Pelger,R.C., and van 
der,P.G. (2010). High aldehyde dehydrogenase activity identifies tumor-initiating 
and metastasis-initiating cells in human prostate cancer. Cancer Res. 70, 5163-5173. 
van Rhenen A., Feller,N., Kelder,A., Westra,A.H., Rombouts,E., Zweegman,S., van der 
Pol,M.A., Waisfisz,Q., Ossenkoppele,G.J., and Schuurhuis,G.J. (2005). High stem 
cell frequency in acute myeloid leukemia at diagnosis predicts high minimal 
residual disease and poor survival. Clin. Cancer Res. 11, 6520-6527. 
Vermeulen,L., Todaro,M., de Sousa,M.F., Sprick,M.R., Kemper,K., Perez,A.M., Richel,D.J., 
Stassi,G., and Medema,J.P. (2008). Single-cell cloning of colon cancer stem cells 
reveals a multi-lineage differentiation capacity. Proc. Natl. Acad. Sci. U. S. A 105, 
13427-13432. 
Vis,A.N., Noordzij,M.A., Fitoz,K., Wildhagen,M.F., Schroder,F.H., and van der Kwast,T.H. 
(2000). Prognostic value of cell cycle proteins p27(kip1) and MIB-1, and the cell 
www.intechopen.com
 Cancer Stem Cells Theories and Practice 
 
360 
adhesion protein CD44s in surgically treated patients with prostate cancer. J. Urol. 
164, 2156-2161. 
Weg-Remers,S., Anders,M., von,L.B., Riecken,E.O., Schuder,G., Feifel,G., Zeitz,M., and 
Stallmach,A. (1998). Decreased expression of CD44 splicing variants in advanced 
colorectal carcinomas. Eur. J. Cancer 34, 1607-1611. 
Weichert,W., Denkert,C., Burkhardt,M., Gansukh,T., Bellach,J., Altevogt,P., Dietel,M., and 
Kristiansen,G. (2005). Cytoplasmic CD24 expression in colorectal cancer 
independently correlates with shortened patient survival. Clin. Cancer Res. 11, 
6574-6581. 
Weichert,W., Knosel,T., Bellach,J., Dietel,M., and Kristiansen,G. (2004). ALCAM/CD166 is 
overexpressed in colorectal carcinoma and correlates with shortened patient 
survival. J. Clin. Pathol. 57, 1160-1164. 
Xin,L., Lawson,D.A., and Witte,O.N. (2005). The Sca-1 cell surface marker enriches for a 
prostate-regenerating cell subpopulation that can initiate prostate tumorigenesis. 
Proc. Natl. Acad. Sci. U. S. A 102, 6942-6947. 
Zeppernick,F., Ahmadi,R., Campos,B., Dictus,C., Helmke,B.M., Becker,N., Lichter,P., 
Unterberg,A., Radlwimmer,B., and Herold-Mende,C.C. (2008). Stem cell marker 
CD133 affects clinical outcome in glioma patients. Clin. Cancer Res. 14, 123-129. 
Zhang,M., Song,T., Yang,L., Chen,R., Wu,L., Yang,Z., and Fang,J. (2008). Nestin and CD133: 
valuable stem cell-specific markers for determining clinical outcome of glioma 
patients. J. Exp. Clin. Cancer Res. 27, 85. 
Zlobec,I., Terracciano,L., Jass,J.R., and Lugli,A. (2007). Value of staining intensity in the 
interpretation of immunohistochemistry for tumor markers in colorectal cancer. 
Virchows Arch. 451, 763-769 
www.intechopen.com
Cancer Stem Cells Theories and Practice
Edited by Prof. Stanley Shostak
ISBN 978-953-307-225-8
Hard cover, 442 pages
Publisher InTech
Published online 22, March, 2011
Published in print edition March, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Cancer Stem Cells Theories and Practice does not 'boldly go where no one has gone before!' Rather, Cancer
Stem Cells Theories and Practice boldly goes where the cutting edge of research theory meets the concrete
challenges of clinical practice. Cancer Stem Cells Theories and Practice is firmly grounded in the latest results
on cancer stem cells (CSCs) from world-class cancer research laboratories, but its twenty-two chapters also
tease apart cancer's vulnerabilities and identify opportunities for early detection, targeted therapy, and
reducing remission and resistance.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Paola Marcato and Patrick W. K. Lee (2011). The Rocky Road from Cancer Stem Cell Discovery to Diagnostic
Applicability, Cancer Stem Cells Theories and Practice, Prof. Stanley Shostak (Ed.), ISBN: 978-953-307-225-8,
InTech, Available from: http://www.intechopen.com/books/cancer-stem-cells-theories-and-practice/the-rocky-
road-from-cancer-stem-cell-discovery-to-diagnostic-applicability
© 2011 The Author(s). Licensee IntechOpen. This chapter is distributed
under the terms of the Creative Commons Attribution-NonCommercial-
ShareAlike-3.0 License, which permits use, distribution and reproduction for
non-commercial purposes, provided the original is properly cited and
derivative works building on this content are distributed under the same
license.
